
    
      This is a multicenter double-blind randomized controlled study on two parallel groups.

      Once inclusion and exclusion criteria verified and after having obtained patient written
      consent, participative centers will process to inclusion in the trial.

      Corticosteroids as well as antibiotics or their placebo will be started orally. Patients will
      be managed in the hospital unit until day 7, which corresponds to the evaluation of response
      to treatment using the Lille model. After this 7-day period, patients will be followed-up at
      day 14, day 21, day 30, day 60 (primary endpoint).

      During each visit, biological and clinical features including efficacy and tolerance will be
      assessed as well as presence of infection and hepatorenal syndrome (secondary endpoints).
    
  